Axon Enterprise - AXON Stock Forecast, Price & News

Axon Enterprise, Inc. develops, manufactures, and sells conducted energy devices (CEDs) under the TASER brand in the United States and internationally. It operates through two segments, TASER, and Software and Sensors. The company also offers hardware and cloud-based software solutions that enable law enforcement to capture, securely store, manage, share, and analyze video and other digital evidence. Its products include TASER 7, TASER X26P, TASER X2, TASER Consumer devices, and related cartridges; on-officer body cameras, Axon Fleet in-car systems, and other devices; Axon Evidence digital evidence management software; Axon Signal enabled devices, as well as hardware extended warranties; and Axon docks, cartridges, and batteries. It sells its products through its direct sales force, distribution partners, online store, and third-party resellers. Axon Enterprise, Inc. has a strategic partnership with Fusus, Inc. to expand the capabilities of Axon Respond and the Fusus Real Time Crime Center in the Cloud solution to provide agencies real-time operations situational awareness, including streamlined investigative workflows. The company was formerly known as TASER International, Inc. and changed its name to Axon Enterprise, Inc. in April 2017. Axon Enterprise, Inc. was incorporated in 1993 and is headquartered in Scottsdale, Arizona.

Axon Enterprise Stock Performance

NASDAQ:AXON traded up $5.39 during mid-day trading on Friday, reaching $129.49. 477,184 shares of the company's stock were exchanged, compared to its average volume of 309,287. Axon Enterprise has a one year low of $82.49 and a one year high of $209.00. The firm has a market capitalization of $9.20 billion, a PE ratio of 66.41 and a beta of 0.66. The business's fifty day simple moving average is $98.96 and its two-hundred day simple moving average is $112.70. The company has a debt-to-equity ratio of 0.02, a quick ratio of 2.18 and a current ratio of 2.70.

Axon Enterprise (NASDAQ:AXON - Get Rating) last released its quarterly earnings results on Tuesday, August 9th. The biotechnology company reported $0.44 EPS for the quarter, topping analysts' consensus estimates of $0.39 by $0.05. Axon Enterprise had a net margin of 14.20% and a return on equity of 12.57%. The business had revenue of $285.61 million for the quarter, compared to analyst estimates of $258.96 million. During the same period last year, the firm earned ($0.72) earnings per share. Axon Enterprise's revenue for the quarter was up 30.5% compared to the same quarter last year. Analysts anticipate that Axon Enterprise will post 1.46 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of analysts have commented on the stock. JMP Securities reiterated a "buy" rating and issued a $195.00 price target on shares of Axon Enterprise in a research note on Wednesday, June 1st. Credit Suisse Group increased their price target on shares of Axon Enterprise from $134.00 to $142.00 and gave the company an "outperform" rating in a research note on Wednesday. StockNews.com upgraded shares of Axon Enterprise from a "hold" rating to a "buy" rating in a research note on Saturday, June 18th. Morgan Stanley cut shares of Axon Enterprise from an "overweight" rating to an "equal weight" rating and set a $120.00 target price for the company. in a research note on Monday, May 23rd. Finally, Northland Securities cut their target price on shares of Axon Enterprise from $180.00 to $130.00 in a research note on Thursday, May 12th. One investment analyst has rated the stock with a hold rating and eight have given a buy rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and an average price target of $163.25.

Insider Buying and Selling at Axon Enterprise

In other Axon Enterprise news, Director Mark W. Kroll sold 3,159 shares of the firm's stock in a transaction dated Wednesday, June 8th. The shares were sold at an average price of $102.82, for a total value of $324,808.38. Following the transaction, the director now directly owns 13,691 shares of the company's stock, valued at approximately $1,407,708.62. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Insiders own 6.90% of the company's stock.